General Information of Drug (ID: DM84AVQ)

Drug Name
CY6463 Drug Info
Synonyms
Zagociguat; Zagociguat [INN]; H7KEN3O8AI; UNII-H7KEN3O8AI; 2201048-82-8; CY6463; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; ZAGOCIGUAT [USAN]; SCHEMBL19922804; GTKNNCQKFKGSHR-UHFFFAOYSA-N; EX-A7620; AKOS040757400; CY-6463; IW-6463; MS-25746; HY-145607; CS-0376702; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Cross-matching ID
PubChem CID
134304734
TTD Drug ID
DM84AVQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [3]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [4]
Sodium nitroprusside DMGA9X0 Hypertension BA00-BA04 Approved [5]
IW-1973 DMK2T7J Heart failure BD10-BD13 Phase 2 [6]
CTI-1601 DMM4JMB Friedreich's ataxia 8A03.10 Phase 2 [7]
Runcaciguat DMCFTTN Chronic kidney disease GB61 Phase 2 [8]
MK-5475 DMIIZ4R Pulmonary arterial hypertension BB01.0 Phase 2 [9]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [4]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [3]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [4]
Sodium nitroprusside DMGA9X0 Hypertension BA00-BA04 Approved [5]
IW-1973 DMK2T7J Heart failure BD10-BD13 Phase 2 [6]
CTI-1601 DMM4JMB Friedreich's ataxia 8A03.10 Phase 2 [7]
Runcaciguat DMCFTTN Chronic kidney disease GB61 Phase 2 [8]
MK-5475 DMIIZ4R Pulmonary arterial hypertension BB01.0 Phase 2 [9]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 16 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Stimulator [2]

References

1 ClinicalTrials.gov (NCT04798989) A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology. U.S.National Institutes of Health.
2 First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
3 Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
4 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
5 Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
8 Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
9 Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.